[1]王孟昭,张紫萱.肺癌的靶向治疗[J].第三军医大学学报,2012,34(20):2035-2038.
 Wang Mengzhao,Zhang Zixuan.Target therapy in lung cancer[J].J Third Mil Med Univ,2012,34(20):2035-2038.
点击复制

肺癌的靶向治疗(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第20期
页码:
2035-2038
栏目:
专家述评
出版日期:
2012-10-30

文章信息/Info

Title:
Target therapy in lung cancer
作者:
王孟昭张紫萱
中国医学科学院中国协和医科大学北京协和医院呼吸内科
Author(s):
Wang Mengzhao Zhang Zixuan
Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China
关键词:
肺癌靶向治疗表皮生长因子受体
Keywords:
lung cancer target therapy epidermal growth factor receptor
分类号:
R730.5;R734.2
文献标志码:
A
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), as a standard target therapy in lung cancer, has been developed as a chemotherapy drug. Many clinical trials with EGFR-TKIs as third line, second line and first line treatment for lung cancer patients were carried out. Only EGFR gene mutations could predict benefit from EGFR-TKIs treatment for patients with lung cancer. Based on the experiences from the development of EGFR-TKIs, Crizotinib (Xalkori, Pfizer) is quickly approved for treatment in some patients with non-small cell lung carcinoma (NSCLC) harboring ALK gene rearrangement in every line. We believe that many other target drugs would be used in clinical practice to treat lung cancer patients. Identification of driver mutations in tumor specimens from Chinese patients is very important. Basic research and drug development in China will be promoted from the discovery of new driver mutations, especially in squamous cell lung cancer and small cell lung cancer. Based on the results of driver mutations tests, Chinese patients will be benefited from global research findings.

参考文献/References:

王孟昭, 张紫萱. 肺癌的靶向治疗[J]. 第三军医大学学报,2012,34(20):2035-2038.

相似文献/References:

[1]谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].第三军医大学学报,2012,34(17):1775.
 Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Third Mil Med Univ,2012,34(20):1775.
[2]莫贵艳,李敏,胡成平,等.茶氨酸对内皮细胞生长及肺癌血管生成的影响[J].第三军医大学学报,2012,34(20):2043.
 Mo Guiyan,Li Min,Hu Chengping,et al.Theanine suppresses angiogenesis of endothelial cells in vitro and in vivo[J].J Third Mil Med Univ,2012,34(20):2043.
[3]刘晓丽,马礼鸿,王全义,等.XIAP、c-jun在肺癌组织中的表达及其意义[J].第三军医大学学报,2012,34(23):2408.
 Liu Xiaoli,Ma Lihong,Wang Quanyi,et al.Expression and clinical significance of XIAP and c-jun in human lung cancer tissues[J].J Third Mil Med Univ,2012,34(20):2408.
[4]李长毅,张明川,梅同华,等.持续小剂量化疗对A549肺癌PTEN基因和凋亡的影响[J].第三军医大学学报,2007,29(18):1760.
 LI Chang-yi,ZHANG Ming-chuan,MEI Tong-hua,et al.Low-dose metronomic chemotherapy upregulates PTEN and induces apoptosis of A549 pulmonary adenocarcinoma in athymic mice[J].J Third Mil Med Univ,2007,29(20):1760.
[5]邓丽平,董文,杜艳萍,等.支气管肺泡灌洗液和血清肿瘤标志物联合检测在肺癌诊断中的价值[J].第三军医大学学报,2008,30(01):78.
 DENG Li-ping,DONG Wen,DU Yan-ping,et al.Combined determination of tumor markers in serum and bronchoalveolar lavage fluid for lung cancer diagnosis[J].J Third Mil Med Univ,2008,30(20):78.
[6]李代蓉,周清华,郭占林,等.CYP2E1基因多态性与肺癌遗传易感性的关系[J].第三军医大学学报,2008,30(13):1231.
 LI Dai-rong,ZHOU Qing-hua,GUO Zhan-lin,et al.Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study[J].J Third Mil Med Univ,2008,30(20):1231.
[7]李艳秋,李建春,关洪全,等.肺癌患者外周血Th1/Th2细胞因子及IL-18水平变化与肿瘤分期的关系[J].第三军医大学学报,2007,29(08):731.
 LI Yan-qiu,LI Jian-chun,GUAN Hong-quan,et al.Changes of IL-18 and Th1/Th2 in serum of lung cancer patients and their relationship with tumor staging[J].J Third Mil Med Univ,2007,29(20):731.
[8]戴纪刚,肖颖彬,闵家新,等.非小细胞肺癌线粒体基因组大片段缺失突变研究[J].第三军医大学学报,2006,28(21):2123.
[9]王红梅,廖国清,雷红,等.晚期肺癌患者肺部感染病原学分析[J].第三军医大学学报,2006,28(20):2103.
[10]高丽莉,胡义德,张青,等.核素骨显像诊断肺癌骨转移的临床价值[J].第三军医大学学报,2006,28(19):2004.

更新日期/Last Update: 2012-10-18